Table 3 Number of respondents reporting use, billing and funding for the 6 genes reimbursed by Medicare and Medicaid
Genes | Used in Research | Reported Clinically | Billing 3rd party | Billing Patients directly | Other coverage – institutional or pilot funding |
|---|---|---|---|---|---|
CYP2C19 | 4 | 13 | 2 | 10 | 7 |
CYP2D6 | 8 | 8 | 1 | 4 | 5 |
HLA B 15 02 (Asian only) | 5 | 3 | 0 | 0 | 2 |
HLA B 57 01 | 5 | 4 | 1 | 1 | 2 |
VK0RC1 | 7 | 6 | 1 | 4 | 6 |
CYP2C9 | 7 | 8 | 1 | 4 | 6 |
Total | 36 | 42 | 6 | 23 | 28 |
Range | 1-8 | 1-8 | 1-7 | 0-4 | 1-6 |
Average # genes tested per site reporting | 4.5 | 5.3 | 0.8 | 2.9 | 3.5 |